Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | APEX1 | P27695 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | FABP4 | P15090 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2005291 | 0.87 | CA1 (0.39) | F2PRSS1PRSS2PRSS3ALOX15 | |
| SCHEMBL6169371 | 0.85 | F2 (0.48) | F2PRSS1PRSS2PRSS3ALOX15 | |
| SCHEMBL7284889 | 0.85 | F2 (0.48) | F2PRSS1PRSS2PRSS3ALOX15 | |
| SCHEMBL11138757 | 0.82 | TRPV4 (0.46) | F2PRSS1PRSS2PRSS3ALOX15 | |
| SCHEMBL39857 | 0.80 | ALDH1A1 (0.55) | ALOX15APEX1ALDH1A1HPGDMAPK1 | |
| SCHEMBL2009654 | 0.79 | ALDH1A1 (0.51) | ALDH1A1MAPK1KDM4ETDP1MEN1 | |
| Hydrochloric Acid SCHEMBL699717 | 0.78 | ALDH1A1 (0.53) | ALOX15APEX1ALDH1A1HPGDMAPK1 | |
| SCHEMBL1586444 | 0.77 | ALOX15 (0.49) | F2PRSS1PRSS2PRSS3ALOX15 | |
| SCHEMBL135801 | 0.76 | CA1 (0.60) | F2PRSS1PRSS2PRSS3ALOX15 | |
| SCHEMBL15313666 | 0.76 | HSD17B10 (0.46) | F2PRSS1PRSS2PRSS3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654837-B2 | Sulphamoylaryl derivatives and use thereof as medicaments for the treatment of liver fibrosis | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-19 | — | — | US | disclosed |
| US-20190345145-A1 | SULPHAMOYLARYL DERIVATIVES AND USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF LIVER FIBROSIS | JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) | 2019-11-14 | — | — | US | disclosed |
| WO-2018145620-A1 | SULPHAMOYLARYL DERIVATIVES AND USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF LIVER FIBROSIS | JANSSEN PHARMACEUTICA NV (BE) | 2018-08-16 | — | — | WO | disclosed |
| EP-1864976-B1 | PROPANE-1,3-DION DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2012-10-10 | — | — | EP | disclosed |
| US-7960562-B2 | Propane-1,3-dione derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-06-14 | — | — | US | disclosed |
| CN-101142193-B | 1, 3-propanedione derivative or salt thereof | ASTELLAS PHARMA INC | 2010-12-29 | — | — | CN | disclosed |
| US-20090181964-A1 | Propane-1,3-Dione Derivative or Salt Thereof | ASTELLAS PHARMA INC. | 2009-07-16 | — | — | US | disclosed |
| CN-101142193-A | 1, 3-propanedione derivative or salt thereof | ASTELLAS PHARMA INC (JP) | 2008-03-12 | — | — | CN | disclosed |
| EP-1864976-A1 | PROPANE-1,3-DION DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654837-B2 | Sulphamoylaryl derivatives and use thereof as medicaments for the treatment of liver fibrosis | HTR2B, HTR3B, HTR1A | F2 981/4885PRSS1 239/4885PRSS2 294/4885 |
| US-20090181964-A1 | Propane-1,3-Dione Derivative or Salt Thereof | GNRHR, KISS1R, FSHR | F2 1765/4885PRSS1 802/4885PRSS2 1576/4885 |
| US-20190345145-A1 | SULPHAMOYLARYL DERIVATIVES AND USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF LIVER FIBROSIS | HTR2B, HTR3B, HTR1A | F2 981/4885PRSS1 239/4885PRSS2 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.